摘要
A B S T R A C T The clinically applicable single uric acid transporter 1 (URAT1) inhibitor or xanthine oxidoreductase (XOR) inhibitor cannot solve the clinical needs in anti-hyperuricemia well. It is expected that combined inhi-bition of both XOR and URAT1 might effectively decrease the level of uric acid and avoid the issue of insufficient potency by single-target drugs. 3D-QSAR pharmacophore modeling, molecular docking, and ADMET filtering were applied for potential dual inhibitors. And top-ranked three compounds were se-lected to MD simulation analysis, with utilization of binding free energy and decomposition data. 4917-2281, 4109-2078 and C301-8913, have potential inhibitory potency for both XOR and URAT1 and were suitable for further experimental analysis and modification.
学科与关键词
- Design, synthesis, and evaluation of the in vitro activity of novel dual inhibitors of XOR and URAT1 containing a benzoic acid groupZhu, Xin Ying; Chen, Hong Ming; Zhang, Lei; Qin, Yu Xiang; Li, Jing*Chemical Biology and Drug Design, 2023, 102(6): 1553-1567.
- Design, Synthesis and Biological Activity of Low-Molecular-Weight URAT1 InhibitorsChen, Siliang; Chen, Ya; Yang, Zhongcheng; Huang, Wanqiu; Cao, Zhijun; Wang, Xuekun; Yao, Huixin; Li, Zheng*; Wang, Guangji*ChemistrySelect, 2023, 8(5).
- Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemiaZhao, Zean; Liu, Jin; Kuang, Peihua; Luo, Jian; Surineni, Goverdhan; Cen, Xiaolin; Wu, Ting; Cao, Ying; Zhou, Pingzheng; Pang, Jianxin*; Zhang, Qun*; Chen, Jianjun*European Journal of Medicinal Chemistry, 2022, 229: 114092.被引 9
